$10.55
-1.06 (-9.13%)
Open$12.01
Previous Close$11.61
Day High$12.08
Day Low$10.53
52W High$14.93
52W Low$5.15
Volume—
Avg Volume146.4K
Market Cap202.89M
P/E Ratio—
EPS$-2.62
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+203.7% upside
Current
$10.55
$10.55
Target
$32.04
$32.04
$22.50
$32.04 avg
$35.39
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 32.29M | 31.67M | 27.66M |
| Net Income | 4.35M | 5.71M | 3.74M |
| Profit Margin | 13.5% | 18.0% | 13.5% |
| EBITDA | 8.33M | 8.25M | 7.51M |
| Free Cash Flow | 3.02M | 4.79M | 4.27M |
| Rev Growth | +12.6% | +22.6% | -0.7% |
| Debt/Equity | 0.19 | 0.18 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |